BTIG analyst Ryan Zimmerman lowered the price target on Humacyte (NASDAQ: HUMA) to $2.00 (from $3.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE